Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Growth in Short Interest

Posted by George Bondi on Aug 19th, 2026

Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 21,284 shares, an increase of 62.6% from the July 15th total of 13,090 shares. Approximately 5.3% of the company’s shares are short sold. Based on an average daily volume of 111,194 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

SLXN has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. Maxim Group lowered Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Read Our Latest Analysis on Silexion Therapeutics

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Silexion Therapeutics stock. Ancora Advisors LLC purchased a new stake in Silexion Therapeutics Corp (NASDAQ:SLXN – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 30,000 shares of the company’s stock, valued at approximately $31,000. Ancora Advisors LLC owned approximately 7.14% of Silexion Therapeutics as of its most recent filing with the Securities & Exchange Commission. 10.95% of the stock is owned by institutional investors and hedge funds.

Silexion Therapeutics Price Performance

SLXN stock traded down $0.01 during trading hours on Wednesday, reaching $0.41. The stock had a trading volume of 61,978 shares, compared to its average volume of 327,864. Silexion Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $80.00. The stock has a market capitalization of $350,880.00, a PE ratio of -0.01 and a beta of -0.25. The stock has a 50-day simple moving average of $2.25 and a 200 day simple moving average of $8.24.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($5.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($21.20) by $16.03. On average, sell-side analysts forecast that Silexion Therapeutics will post -45.5 EPS for the current fiscal year.

About Silexion Therapeutics

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.